Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Uso de quimioterapia durante el embarazo
Resumen
La presencia de tumores malignos durante la gestación complica tanto el manejo como el propio embarazo, ya que cualquier intervención diagnóstica o terapéutica puede conllevar riesgos que puedan generar efectos nocivos para la madre o para el feto. Los riesgos que tiene un feto sometido a la administración de la terapia citotóxica se correlacionan directamente con la edad gestacional y con el tiempo de la exposición intrauterina a la misma. El tratamiento antineoplásico busca dos objetivos principales; el primero es el control local por medio de cirugía complementada con radioterapia; el segundo busca erradicar la enfermedad sistémica a través de quimioterapia, inmunoterapia, hormonoterapia o terapias blanco.
Palabras clave
Referencias
Gabbe SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ERM, et al. Obstetrics: Normal and Problem Pregnancies. Sixth edition. Philadelphia, PA, USA: Elsevier; 2012. pp. 1256-1276.
Gerson R, Serrano A, Flores VF, Villalobos A. Quimioterapia en cáncer durante el embarazo. Anales Medicos. 2006;61:29-32.
DeVita VT, LawrenceTS, Rosenberg SA. Cancer: Principles & Practice of Oncology. 8th Edition. Philadelphia, PA, USA: Wolters Kluwer/Lippincott Williams & Wilkins; 2008.
Cohn D, Ramaswamy B, Blum K. Malignancy and pregnancy. In: Creasy RK, Resnik R, Iams JD, et al. (eds.). Creasy & Resnik’s maternal fetal medicine: Principles and practice. Sixth edition. Philadelphia, PA, USA: Saunders; 2009. pp. 885-904.
Muñoz MC. Uso de Quimioterapia en el embarazo (Caso clínico y revisión bibliográfica). Revista Medica de Costa Rica y Centroamérica. 2010;LXVII(592):207-10.
Perry MC. The chemotherapy source book. Fourth edition. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2008.
Amant F, Loibl S, Neven P, Van Calsteren K. Breast Cancer During Pregnancy. Lancet. 2012;379:570-9.
Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG. Williams Ginecología. Neoplasias. McGraw- Hill. 2008;13: 1193-1206.
Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012 Nov 10;30(32):4017-25. doi: 10.1200/JCO.2012.43.5362.
Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 1989;28:113-21.
Nygren P; SBU-group. Swedish Council on Technology Assessment in Health Care. What is cancer chemotherapy? Acta Oncol. 2001;40(2-3):166-74.
Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 1996;32A:912-9.
Godoy-Rivera LM. Biología Molecular en cáncer. Clínicas Oncológicas de Iberoamérica. P DESA; 2008. pp. 29-36.
Jones PA. Overview of cancer epigenetics. Semin Hematol. 2005 Jul;42(3 Suppl 2):S3-8.
Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009 Jan;7(1):99-108.
Frei E 3rd, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585-94.
Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996 Sep;14(9):2590-611.
Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002 Apr 22;86(8):1297-302.
Gurney H. I don’t underdose my patients... do I? Lancet Oncol. 2005;6:637-8.
Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer. 2007 Aug 28; 97(5): 577-81. doi: 10.1038/sj.bjc.6603925
Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8.
Theriault R, Hahn K. Management of breast cancer in pregnancy. Curr Oncol Rep. 2007 Jan;9(1):17-21.
Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am. 2005 Dec;32(4):627-40.
Food and Drug Administration. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy. Disponible en volunteers.www.fda.gov/downloads/Drugs/Guidance/UCM078932.pdf
Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, et al. Cancer chemotherapeutic agents as human teratogens. Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):626-50. doi: 10.1002/bdra.23063.
Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer. 2008 Dec 1;113(11):3069-74. doi: 10.1002/cncr.23935.
Cancer Care Ontario, Cancer in young adults in Canada. Toronto: Cancer Care Ontario; 2006. May 2006.
Santucci AK, Gold MA, Akers AY, Borrero S, Schwarz EB. Women’s perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2009;88:64-9.
Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34:302-12.
Azim HA, Peccatori FA. Managing cancer during pregnancy: what evidence do we have? Pol Arch Med Wewn. 2011;121:29-34.
Leslie KK. Chemotherapy and pregnancy. Clin Obstet Gynecol. 2002;45(1):153-64.
Koren G. Fetal risks of maternal pharmacotherapy: identifying signals. Handb Exp Pharmacol. 2011;205:285-94.
Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol. 2009;113(1):166-88.
Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ER. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988;72(3 Pt2):462-4.
Missailidis S (ed.). Anticancer therapeutics. First edition. Chichester, West Sussex, UK: John Wiley & Sons; 2008.
Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V; Society of Obstetricians and Gynaecologists of Canada. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013 Mar;35(3):263-80.
Cole S, Kantarjian H, Ault P, Cortes JE. Successful completion of pregnancy in patient with CML without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009;9(4):324-7.
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-506.
Pentheroudakis G. Cancer and pregnancy. Ann Oncol. 2008;19(5):v38-v39.
Enlaces refback
- No hay ningún enlace refback.